The term ‘small molecule’ or low-molecular-weight organic compound means that the drug can be administered orally or that it can be injected through parenteral routes. Small-molecule injectable drugs are used in the treatment of oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases.
Moreover, the small-molecule drugs are very easy to synthesize and can be produced in large quantities and also these drugs are very simple to manufacture, which leads to strong generic competition among market players. As small molecules typically work by mimicking biological substrates or allosterically targeting hydrophobic pockets of proteins, certain biological targets may not be druggable. Many bacterial and cancer cells have developed resistance to small-molecule drugs through mechanisms such as chemoenzymatic modifications, efflux pumps, drug target mutations, etc.
Market Dynamics
Market players are initiating production of injectable drugs in the new manufacturing facility, which is expected to drive growth of the global small molecule injectable drugs, over the forecast period. For instance, in August 2018, Pfizer Inc., a pharmaceutical and Biotechnology Corporation, announced injectable production at Portage in Kalamazoo, Michigan. The plant will enable Pfizer to produce injectable medicines for patients suffering from chronic diseases such as oncology, across the globe, as well as supporting the company’s supply capacity and production.
Key players are involved in receiving approvals from regulatory authorities for new small molecule injectable drugs. This is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance in October 2020, Aurobindo Pharma Ltd., a pharmaceutical company, announced that they received approval from the U.S. Food and Drug Administration for its generic acetaminophen injection. It is indicated for the treatment of pain in pediatric patients and adults.
Moreover, in 2018, Aurobindo Pharma Ltd. announced that they received approval from U.S. Food and Drug Administration to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg for the U.S. markets. This drug is utilized as a part of general anesthesia to give skeletal muscle relaxation during mechanical ventilation or surgery.
Key features of the study:
- This report provides an in-depth analysis of the global small molecule injectable drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global small molecule injectable drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc
- Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global small molecule injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule injectable drugs market
Detailed Segmentation:
- Global Small Molecule Injectable Drugs Market, By Drug Class:
- Chemotherapy
- Small Molecule Antibiotics
- Skeletal Muscle Relaxants
- Analgesics
- Anticoagulants
- Anticonvulsants
- Antivirals
- Others
- Global Small Molecule Injectable Drugs Market, By Indication:
- Oncology
- Pain Management
- Cardiovascular Diseases
- Infectious Diseases
- CNS Diseases
- Others
- Global Small Molecule Injectable Drugs Market, By Mode of Delivery:
- IV Set
- Infusion Pump
- Intravenous Injection
- Intramuscular Injection
- Subcutaneous Injection
- Global Small Molecule Injectable Drugs Market, By End User:
- Hospitals
- Ambulatory Clinics
- Outpatient Facility
- Infusion Therapy Center
- Home Care
- Others
- Global Small Molecule Injectable Drugs Market, By Region:
- North America
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis AG *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AstraZeneca Plc
- Baxter International Inc.
- Fresenius Kabi AG
- Cipla Limited.
- Mylan N.V.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Sanofi S.A.
- Reddy’s Laboratories Ltd.
- Hoffmann-La Roche AG (Genentech, Inc.)
- Amgen, Inc.
- Gilead Sciences, Inc.
- Hikma Pharmaceuticals plc
“*” marked represents similar segmentation in other categories in the respective section.
